Analysts have been desirous to weigh in on the Healthcare sector with new rankings on Johnson & Johnson (JNJ – Analysis Report) and Ionis Prescribed drugs (IONS – Analysis Report).
Johnson & Johnson (JNJ)
In a report issued on February 13, Jayson Bedford from Raymond James maintained a Purchase score on Johnson & Johnson. The corporate’s shares closed final Friday at $146.36.
In keeping with TipRanks.com, Bedford is a 5-star analyst with a mean return of 15.2% and a 68.9% success fee. Bedford covers the Healthcare sector, specializing in stocks comparable to Cardiovascular Methods, Benefit Medical Methods, and Integra Lifesciences.
Presently, the analyst consensus on Johnson & Johnson is a Sturdy Purchase with a mean price goal of $172.50, a 17.3% upside from present ranges. In a report issued on May 28, Goldman Sachs additionally initiated protection with a Purchase score on the stock with a $163.00 price goal.
See at present’s analyst prime really helpful stocks >>
Ionis Prescribed drugs (IONS)
In a report issued on November 4, Myles Minter from William Blair maintained a Maintain score on Ionis Prescribed drugs. The corporate’s shares closed final Friday at $49.14.
In keeping with TipRanks.com, Minter is a 4-star analyst with a mean return of 19.6% and a 60.0% success fee. Minter covers the Healthcare sector, specializing in stocks comparable to Minerva Neurosciences, Prevail Therapeutics, and Silence Therapeutics.
The phrase on The Street usually, suggests a Average Purchase analyst consensus score for Ionis Prescribed drugs with a $66.60 common price goal, representing a 32.6% upside. In a report issued on November 5, Leerink Companions additionally maintained a Maintain score on the stock with a $50.00 price goal.
TipRanks has tracked 36,00Zero firm insiders and located that a couple of of them are higher than others in relation to timing their transactions. See which 3 stocks are more than likely to make strikes following their insider actions.